Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' SCHWARTZ JC' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 182 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Stark, H; Krause, M; Rouleau, A; Garbarg, M; Schwartz, JC; Schunack, W
      Enzyme-catalyzed prodrug approaches for the histamine H-3-receptor agonist(R)-alpha-methylhistamine

      BIOORGANIC & MEDICINAL CHEMISTRY
    2. Stark, H; Sippl, W; Ligneau, X; Arrang, JM; Ganellin, CR; Schwartz, JC; Schunack, W
      Different antagonist binding properties of human and rat histamine H-3 receptors

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    3. Tardivel-Lacombe, J; Morisset, S; Gbahou, F; Schwartz, JC; Arrang, JM
      Chromosomal mapping and organization of the human histamine H-3 receptor gene

      NEUROREPORT
    4. Beardsley, PM; Sokoloff, P; Balster, RL; Schwartz, JC
      The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered

      BEHAVIOURAL PHARMACOLOGY
    5. Meier, G; Apelt, J; Reichert, U; Grassmann, S; Ligneau, X; Elz, S; Leurquin, F; Ganellin, CR; Schwartz, JC; Schunack, W; Stark, H
      Influence of imidazole replacement in different structural classes of histamine H-3-receptor antagonists

      EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
    6. Heron, A; Rouleau, A; Cochois, V; Pillot, C; Schwartz, JC; Arrang, JM
      Expression analysis of the histamine H-3 receptor in developing rat tissues

      MECHANISMS OF DEVELOPMENT
    7. Schwartz, JC; Morisset, S; Rouleau, A; Tardivel-Lacombe, J; Gbahou, F; Ligneau, X; Heron, A; Sasse, A; Stark, H; Schunack, W; Ganellin, RC; Arrang, JM
      Application of genomics to drug design: the example of the histamine H-3 receptor

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    8. Sasse, A; Ligneau, X; Sadek, B; Elz, S; Pertz, HH; Ganellin, CR; Arrang, JM; Schwartz, JC; Schunack, W; Stark, H
      Benzophenone derivatives and related compounds as potent histamine H-3-receptor antagonists and potential PET/SPECT ligands

      ARCHIV DER PHARMAZIE
    9. Monteil, T; Danvy, D; Plaquevent, JC; Duhamel, L; Duhamel, P; Gros, C; Schwartz, JC; Lecomte, JM
      New asymmetric synthesis of dexecadotril and ecadotril starting from a single precursor

      SYNTHETIC COMMUNICATIONS
    10. Guillin, O; Diaz, J; Carroll, P; Griffon, N; Schwartz, JC; Sokoloff, P
      BDNF controls dopamine D-3 receptor expression and triggers behavioural sensitization

      NATURE
    11. Morisset, S; Sasse, A; Gbahou, F; Heron, A; Ligneau, X; Tardivel-Lacombe, J; Schwartz, JC; Arrang, JM
      The rat H-3 receptor: Gene organization and multiple isoforms

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    12. Bralet, J; Schwartz, JC
      Vasopeptidase inhibitors: an emerging class of cardiovascular drugs

      TRENDS IN PHARMACOLOGICAL SCIENCES
    13. Krebs, MO; Guillin, O; Bourdel, MC; Schwartz, JC; Olie, JP; Poirier, MF; Sokoloff, P
      Brain Derived Neurotrophic Factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia

      MOLECULAR PSYCHIATRY
    14. Lammers, CH; Diaz, J; Schwartz, JC; Sokoloff, P
      Selective increase of dopamine D-3 receptor gene expression as a common effect of chronic antidepressant treatments

      MOLECULAR PSYCHIATRY
    15. Ito, C; Morisset, S; Krebs, MO; Olie, JP; Loo, H; Poirier, MF; Lannfelt, L; Schwartz, JC; Arrang, JM
      Histamine H-2 receptor gene variants: lack of association with schizophrenia

      MOLECULAR PSYCHIATRY
    16. Sasse, A; Stark, H; Ligneau, X; Elz, S; Reidemeister, S; Ganellin, CR; Schwartz, JC; Schunack, W
      (Partial) agonist/antagonist properties of novel diarylalkyl carbamates onhistamine H-3 receptors

      BIOORGANIC & MEDICINAL CHEMISTRY
    17. Stark, H; Ligneau, X; Sadek, B; Ganellin, CR; Arrang, JM; Schwartz, JC; Schunack, W
      Analogues and derivatives of ciproxifan, a novel prototype for generating potent histamine H-3-receptor antagonists

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    18. Tardivel-Lacombe, J; Rouleau, A; Heron, A; Morisset, S; Pillot, C; Cochois, V; Schwartz, JC; Arrang, JM
      Cloning and cerebral expression of the guinea pig histamine H-3 receptor: evidence for two isoforms

      NEUROREPORT
    19. Arrang, JM; Schwartz, JC
      Untitled - Reply

      NEUROREPORT
    20. Perachon, S; Betancur, C; Pilon, C; Rostene, W; Schwartz, JC; Sokoloff, P
      Role of dopamine D-3 receptors in thermoregulation: a reappraisal

      NEUROREPORT
    21. Bordet, R; Ridray, S; Schwartz, JC; Sokoloff, P
      Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats

      EUROPEAN JOURNAL OF NEUROSCIENCE
    22. Drutel, G; Kathmann, M; Heron, A; Gros, C; Mace, S; Schwartz, JC; Arrang, JM
      Two splice variants of the hypoxia-inducible factor HIF-1 alpha as potential dimerization partners of ARNT2 in neurons

      EUROPEAN JOURNAL OF NEUROSCIENCE
    23. Le Foll, B; Schwartz, JC; Sokoloff, P
      Dopamine D-3 receptor agents as potential new medications for drug addiction

      EUROPEAN PSYCHIATRY
    24. Schwartz, JC
      Racecadotril: a new approach to the treatment of diarrhoea

      INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
    25. Diaz, J; Pilon, C; Le Foll, B; Gros, C; Triller, A; Schwartz, JC; Sokoloff, P
      Dopamine D-3 receptors expressed by all mesencephalic dopamine neurons

      JOURNAL OF NEUROSCIENCE
    26. Laurent, S; Boutouyrie, P; Azizi, M; Marie, C; Gros, C; Schwartz, JC; Lecomte, JM; Bralet, J
      Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin andangiotensin-converting enzyme, in rats and humans

      HYPERTENSION
    27. Schwartz, JC; Diaz, J; Pilon, C; Sokoloff, P
      Possible implications of the dopamine D-3 receptor in schizophrenia and inantipsychotic drug actions

      BRAIN RESEARCH REVIEWS
    28. Kiec-Kononowicz, K; Wiecek, M; Sasse, A; Ligneau, X; Elz, S; Ganellin, CR; Schwartz, JC; Stark, H; Schunack, W
      Importance of the lipophilic group in carbamates having histamine H-3-receptor antagonist activity

      PHARMAZIE
    29. Reidemeister, S; Stark, H; Ligneau, X; Ganellin, CR; Schwartz, JC; Schunack, W
      Substituted N-phenylcarbamates as histamine H-3 receptor antagonists with improved in vivo potency

      PHARMAZIE
    30. Morisset, S; Rouleau, A; Ligneau, X; Gbahou, F; Tardivel-Lacombe, J; Stark, H; Schunack, W; Ganellin, CR; Schwartz, JC; Arrang, JM
      High constitutive activity of native H-3 receptors regulates histamine neurons in brain

      NATURE
    31. Rouleau, A; Stark, H; Schunack, W; Schwartz, JC
      Anti-inflammatory and antinociceptive properties of BP 2-94, a histamine H-3-receptor agonist prodrug

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    32. Morisset, S; Traiffort, E; Arrang, JM; Schwartz, JC
      Changes in histamine H-3 receptor responsiveness in mouse brain

      JOURNAL OF NEUROCHEMISTRY
    33. Ganellin, CR; Bishop, PB; Bambal, RB; Chan, SMT; Law, JK; Marabout, B; Luthra, PM; Moore, ANJ; Peschard, O; Bourgeat, P; Rose, C; Vargas, F; Schwartz, JC
      Inhibitors of tripeptidyl peptidase II. 2. Generation of the first novel lead inhibitor of cholecystokinin-8-inactivating peptidase: A strategy for the design of peptidase inhibitors

      JOURNAL OF MEDICINAL CHEMISTRY
    34. Stark, H; Sadek, B; Krause, M; Huls, A; Ligneau, X; Ganellin, CR; Arrang, JM; Schwartz, JC; Schunack, W
      Novel histamine H-3-receptor antagonists with carbonyl-substituted 4-(3-(phenoxy)propyl)-1H-imidazole structures like ciproxifan and related compounds

      JOURNAL OF MEDICINAL CHEMISTRY
    35. Sasse, A; Sadek, B; Ligneau, X; Elz, S; Pertz, HH; Luger, P; Ganellin, CR; Arrang, JM; Schwartz, JC; Schunack, W; Stark, H
      New histamine H-3-receptor ligands of the proxifan series: Imoproxifan andother selective antagonists with high oral in vivo potency

      JOURNAL OF MEDICINAL CHEMISTRY
    36. Ligneau, X; Morisset, S; Tardivel-Lacombe, J; Gbahou, F; Ganellin, CR; Stark, H; Schunack, W; Schwartz, JC; Arrang, JM
      Distinct pharmacology of rat and human histamine H-3 receptors: role of two amino acids in the third transmembrane domain

      BRITISH JOURNAL OF PHARMACOLOGY
    37. Ouimet, T; Facchinetti, PT; Rose, C; Bonhomme, MC; Gros, C; Schwartz, JC
      Neprilysin II: A putative novel metalloprotease and its isoforms in CNS and testis (vol 271, pg 565, 2000)

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    38. Tanja, O; Facchinetti, P; Rose, C; Bonhomme, MC; Gros, C; Schwartz, JC
      Neprilysin II: A putative novel metalloprotease and its isoforms in CNS and testis

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    39. Drutel, G; Heron, A; Kathmann, M; Gros, C; Mace, S; Plotkine, M; Schwartz, JC; Arrang, JM
      ARNT2, a transcription factor for brain neuron survival?

      EUROPEAN JOURNAL OF NEUROSCIENCE
    40. Lopez, LL; Tiller, PR; Senko, MW; Schwartz, JC
      Automated strategies for obtaining standardized collisionally induced dissociation spectra on a benchtop ion trap mass spectrometer

      RAPID COMMUNICATIONS IN MASS SPECTROMETRY
    41. Allard, J; Barron, S; Trottier, S; Cervera, P; Daumas-Duport, C; Leguern, E; Brice, A; Schwartz, JC; Sokoloff, P
      Edg-2 in myelin-forming cells: Isoforms, genomic mapping, and exclusion inCharcot-Marie-Tooth disease

      GLIA
    42. Sokoloff, P; Schwartz, JC
      A new therapeutic weapon against drug addiction

      M S-MEDECINE SCIENCES
    43. Facchinetti, P; Rose, C; Rostaing, P; Triller, A; Schwartz, JC
      Immunolocalization of tripeptidyl peptidase II, a cholecystokinin-inactivating enzyme, in rat brain

      NEUROSCIENCE
    44. Matzanke, N; Lowe, W; Perachon, S; Sokoloff, P; Schwartz, JC; Stark, H
      Heterocyclic congeners of PD 128,907 with a partially hydrogenated benzomorpholine moiety as potential dopamine D-3-receptor ligands

      EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
    45. Soldani, G; Bertini, S; Rouleau, A; Schwartz, JC; Coruzzi, G
      Gastric antisecretory effects of compound BP 2-94 - A histamine H-3-receptor agonist prodrug

      DIGESTIVE DISEASES AND SCIENCES
    46. Pilla, M; Perachon, S; Sautel, F; Garrido, F; Mann, A; Wermuth, CG; Schwartz, JC; Everitt, BJ; Sokoloff, P
      Selective inhibition of cocaine-seeking behaviour by a partial dopamine D-3 receptor agonist (vol 400, pg 371, 1999)

      NATURE
    47. Pilla, M; Perachon, S; Sautel, F; Garrido, F; Mann, A; Wermuth, CG; Schwartz, JC; Everitt, BJ; Sokoloff, P
      Selective inhibition of cocaine-seeking behaviour by a partial dopamine D-3 receptor agonist

      NATURE
    48. Morisset, S; Sahm, UG; Traiffort, E; Tardivel-Lacombe, J; Arrang, JM; Schwartz, JC
      Atypical neuroleptics enhance histamine turnover in brain via 5-hydroxytryptamine(2A) receptor blockade

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    49. Sasse, A; Kiec-Kononowicz, K; Stark, H; Motyl, M; Reidemeister, S; Ganellin, CR; Ligneau, X; Schwartz, JC; Schunack, W
      Development of chiral N-alkylcarbamates as new leads for potent and selective H-3-receptor antagonists: Synthesis, capillary electrophoresis, and in vitro and oral in vivo activity

      JOURNAL OF MEDICINAL CHEMISTRY
    50. Sasse, A; Stark, H; Reidemeister, S; Huls, A; Elz, S; Ligneau, X; Ganellin, CR; Schwartz, JC; Schunack, W
      Novel partial agonists for the histamine H-3 receptor with high in vitro and in vivo activity

      JOURNAL OF MEDICINAL CHEMISTRY
    51. Perachon, S; Schwartz, JC; Sokoloff, P
      Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D-1, D-2 and D-3 receptors

      EUROPEAN JOURNAL OF PHARMACOLOGY
    52. Marie, C; Mossiat, C; Gros, C; Schwartz, JC; Lecomte, JM; Bralet, J
      Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction

      CARDIOVASCULAR RESEARCH
    53. DUAUX E; GORWOOD P; GRIFFON N; BOURDEL MC; SAUTEL F; SOKOLOFF P; SCHWARTZ JC; ADES J; LOO H; POIRIER MF
      HOMOZYGOSITY AT THE DOPAMINE D-3 RECEPTOR GENE IS ASSOCIATED WITH OPIATE DEPENDENCE

      Molecular psychiatry
    54. KREBS MO; SAUTEL F; BOURDEL MC; SOKOLOFF P; SCHWARTZ JC; OLIE JP; LOO H; POIRIER MF
      DOPAMINE D-3 RECEPTOR GENE VARIANTS AND SUBSTANCE-ABUSE IN SCHIZOPHRENIA

      Molecular psychiatry
    55. STARK H; LIGNEAU X; ARRANG JM; SCHWARTZ JC; SCHUNACK W
      GENERAL CONSTRUCTION PATTERN OF HISTAMINE H-3-RECEPTOR ANTAGONISTS - CHANGE OF A PARADIGM

      Bioorganic & medicinal chemistry letters
    56. RIDRAY S; GRIFFON N; MIGNON V; SOUIL E; CARBONI S; DIAZ J; SCHWARTZ JC; SOKOLOFF P
      COEXPRESSION OF DOPAMINE D-1 AND D-3 RECEPTORS IN ISLANDS OF CALLEJA AND SHELL OF NUCLEUS-ACCUMBENS OF THE RAT - OPPOSITE AND SYNERGISTIC FUNCTIONAL INTERACTIONS

      European journal of neuroscience
    57. ALLARD J; BARRON S; DIAZ J; LUBETZKI C; ZALC B; SCHWARTZ JC; SOKOLOFF P
      A RAT G-PROTEIN-COUPLED RECEPTOR SELECTIVELY EXPRESSED IN MYELIN-FORMING CELLS

      European journal of neuroscience
    58. DREXLER DM; TILLER PR; WILBERT SM; BRAMBLE FQ; SCHWARTZ JC
      AUTOMATED IDENTIFICATION OF ISOTOPICALLY LABELED PESTICIDES AND METABOLITES BY INTELLIGENT REAL-TIME LIQUID-CHROMATOGRAPHY TANDEM MASS-SPECTROMETRY USING A BENCH-TOP ION-TRAP MASS-SPECTROMETER

      Rapid communications in mass spectrometry
    59. STARK H; HULS A; LIGNEAU X; PURAND K; PERTZ H; ARRANG JM; SCHWARTZ JC; SCHUNACK W
      DEVELOPMENT OF FUB-181, A SELECTIVE HISTAMINE H-3-RECEPTOR ANTAGONISTOF HIGH ORAL IN-VIVO POTENCY WITH 4-(OMEGA-(ARYLALKYLOXY)ALKYL)-1H-IMIDAZOLE STRUCTURE

      Archiv der pharmazie
    60. Ganellin, CR; Leurquin, F; Piripitsi, A; Arrang, JM; Garbarg, M; Ligneau, X; Schunack, W; Schwartz, JC
      Synthesis of potent non-imidazole histamine H-3-receptor antagonists

      ARCHIV DER PHARMAZIE
    61. Arrang, JM; Morisset, S; Pillot, C; Schwartz, JC
      Subclassification of histamine receptors, H-3-receptor subtypes? Localization of H-3 receptors in the brain

      HISTAMINE H3 RECEPTOR
    62. SCHWARTZ JC; DIAZ J; BORDET R; GRIFFON N; PERACHON S; PILON C; RIDRAY S; SOKOLOFF P
      FUNCTIONAL IMPLICATIONS OF MULTIPLE DOPAMINE-RECEPTOR SUBTYPES - THE D-1 D-3 RECEPTOR COEXISTENCE/

      Brain research reviews
    63. KREBS MO; GUILLIN O; SOKOLOFF P; BOURDEL MC; SCHWARTZ JC; OLIE JP; LOO H; POIRIER MF
      ASSOCIATION STUDY OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) POLYMORPHISM IN SCHIZOPHRENIA

      American journal of medical genetics
    64. DUBERTRET C; GORWOOD P; ADES J; FEINGOLD J; SCHWARTZ JC; SOKOLOFF P
      METAANALYSIS OF DRD3 GENE AND SCHIZOPHRENIA - ETHNIC HETEROGENEITY AND SIGNIFICANT ASSOCIATION IN CAUCASIANS

      American journal of medical genetics
    65. PERACHON S; SCHWARTZ JC; SOKOLOFF P
      BINDING AND FUNCTIONAL POTENCIES OF BROMOCRIPTINE, PRAMIPEXOLE, PERGOLIDE AND ROPINIROLE AT D-1, D-2 AND D-3 RECEPTORS

      Neurology
    66. SCHWARTZ JC; DIAZ J; BORDET R; GRIFFON N; PERACHON S; PILON C; RIDRAY S; SOKOLOFF P
      THE D-3 RECEPTOR AND ITS LIGANDS

      Naunyn-Schmiedeberg's archives of pharmacology
    67. MORISSET S; SAHM UG; TRAIFFORT E; TROTTIER S; ARRANG JM; SCHWARTZ JC
      EFFECT OF ATYPICAL NEUROLEPTICS ON HISTAMINERGIC NEURON ACTIVITY - EVIDENCE FOR SEROTONIN IMPLICATION

      Naunyn-Schmiedeberg's archives of pharmacology
    68. STARK H; ELZ S; PERTZ H; LIGNEAU X; ARRANG JM; SCHWARTZ JC; SCHUNACK W
      CIPROXIFAN, A SELECTIVE ANTAGONIST OF HIGH IN-VITRO AND IN-VIVO POTENCY AT HISTAMINE H-3-RECEPTORS

      Naunyn-Schmiedeberg's archives of pharmacology
    69. MORISSET S; SAHM UG; TRAIFFORT E; TROTTIER S; ARRANG JM; SCHWARTZ JC
      EFFECT OF ATYPICAL NEUROLEPTICS ON HISTAMINERGIC NEURON ACTIVITY - EVIDENCE FOR SEROTONIN IMPLICATION

      Naunyn-Schmiedeberg's archives of pharmacology
    70. LIGNEAU X; LIN JS; VANNIMERCIER G; JOUVET M; MUIR JL; GANELLIN CR; STARK H; ELZ S; SCHUNACK W; SCHWARTZ JC
      NEUROCHEMICAL AND BEHAVIORAL-EFFECTS OF CIPROXIFAN, A POTENT HISTAMINE H-3-RECEPTOR ANTAGONIST

      The Journal of pharmacology and experimental therapeutics
    71. KRAUSE M; LIGNEAU X; STARK H; GARBARG M; SCHWARTZ JC; SCHUNACK W
      4-ALKYNYLPHENYL IMIDAZOLYLPROPYL ETHERS AS SELECTIVE HISTAMINE H-3-RECEPTOR ANTAGONISTS WITH HIGH ORAL CENTRAL-NERVOUS-SYSTEM ACTIVITY

      Journal of medicinal chemistry
    72. SUZUKI M; HURD YL; SOKOLOFF P; SCHWARTZ JC; SEDVALL G
      D-3 DOPAMINE-RECEPTOR MESSENGER-RNA IS WIDELY EXPRESSED IN THE HUMAN BRAIN

      Brain research
    73. BRUINSSLOT L; GORWOOD P; BOUVARD M; BLOT P; ADES J; FEINGOLD J; SCHWARTZ JC; MOURENSIMEONI MC
      LACK OF ASSOCIATION BETWEEN ANOREXIA-NERVOSA AND D3 DOPAMINE-RECEPTORGENE

      Biological psychiatry
    74. CAINE SB; KOOB GF; PARSONS LH; EVERITT BJ; SCHWARTZ JC; SOKOLOFF P
      D-3 RECEPTOR TEST IN-VITRO PREDICTS DECREASED COCAINE SELF-ADMINISTRATION IN RATS

      NeuroReport
    75. VIZUETE ML; TRAIFFORT E; BOUTHENET ML; RUAT M; SOUIL E; TARDIVELLACOMBE J; SCHWARTZ JC
      DETAILED MAPPING OF THE HISTAMINE H-2-RECEPTOR AND ITS GENE TRANSCRIPTS IN GUINEA-PIG BRAIN

      Neuroscience
    76. DIMITRIADOU V; ROULEAU A; TUONG MDT; NEWLANDS GJF; MILLER HRP; LUFFAU G; SCHWARTZ JC; GARBARG M
      FUNCTIONAL-RELATIONSHIPS BETWEEN SENSORY NERVE-FIBERS AND MAST-CELLS OF DURA-MATER IN NORMAL AND INFLAMMATORY CONDITIONS

      Neuroscience
    77. ROULEAU A; DIMITRIADOU V; TUONG MDT; NEWLANDS GFJ; MILLER HRP; SCHWARTZ JC; GARBARG M
      MAST-CELL SPECIFIC PROTEASES IN RAT-BRAIN - CHANGES IN RATS WITH EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS

      Journal of neural transmission
    78. DIAZ J; RIDRAY S; MIGNON V; GRIFFON N; SCHWARTZ JC; SOKOLOFF P
      SELECTIVE EXPRESSION OF DOPAMINE D-3 RECEPTOR MESSENGER-RNA IN PROLIFERATIVE ZONES DURING EMBRYONIC-DEVELOPMENT OF THE RAT-BRAIN

      The Journal of neuroscience
    79. KREBS MO; SAUTEL F; BOURDEL MC; SOKOLOFF P; SCHWARTZ JC; OLIE JP; LOO H; POIRIER MF
      DOPAMINE D3 RECEPTOR GENE VARIANTS AND PHARMACOSENSITIVE SCHIZOPHRENIC-PATIENTS

      American journal of medical genetics
    80. SCHEY KL; FOWLER JG; SCHWARTZ JC; BUSMAN M; DILLON J; CROUCH RK
      COMPLETE MAP AND IDENTIFICATION OF THE PHOSPHORYLATION SITE OF BOVINELENS MAJOR INTRINSIC PROTEIN

      Investigative ophthalmology & visual science
    81. STARK H; HULS A; LIGNEAU X; ARRANG JM; SCHWARTZ JC; SCHUNACK W
      SEARCH FOR NOVEL LEADS FOR HISTAMINE H-3 RECEPTOR ANTAGONISTS - OXYGEN-CONTAINING DERIVATIVES

      Die Pharmazie
    82. STARK H; LIGNEAU X; LIPP R; ARRANG JM; SCHWARTZ JC; SCHUNACK W
      SEARCH FOR NOVEL LEADS FOR HISTAMINE H-3 RECEPTOR ANTAGONISTS - AMINEDERIVATIVES

      Die Pharmazie
    83. HILL SJ; GANELLIN CR; TIMMERMAN H; SCHWARTZ JC; SHANKLEY NP; YOUNG JM; SCHUNACK W; LEVI R; HAAS HL
      INTERNATIONAL UNION OF PHARMACOLOGY .13. CLASSIFICATION OF HISTAMINE-RECEPTORS

      Pharmacological reviews
    84. BORDET R; RIDRAY S; CARBON S; DIAZ J; SOKOLOFF P; SCHWARTZ JC
      INDUCTION OF DOPAMINE D-3 RECEPTOR EXPRESSION AS A MECHANISM OF BEHAVIORAL SENSITIZATION TO LEVODOPA

      Proceedings of the National Academy of Sciences of the United Statesof America
    85. ROULEAU A; GARBARG M; LIGNEAU X; MANTION C; LAVIE P; ADVENIER C; LECOMTE JM; KRAUSE M; STARK H; SCHUNACK W; SCHWARTZ JC
      BIOAVAILABILITY, ANTINOCICEPTIVE AND ANTIINFLAMMATORY PROPERTIES OF BP-2-94, A HISTAMINE H-3 RECEPTOR AGONIST PRODRUG

      The Journal of pharmacology and experimental therapeutics
    86. GRIFFON N; PILON C; SAUTEL F; SCHWARTZ JC; SOKOLOFF P
      2 INTRACELLULAR SIGNALING PATHWAYS FOR THE DOPAMINE D-3-RECEPTOR - OPPOSITE AND SYNERGISTIC INTERACTIONS WITH CYCLIC-AMP

      Journal of neurochemistry
    87. GANELLIN CR; ROSE C; VARGAS F; FACCHINETTI P; BOURGEAT P; BAMBAL R; BISHOP PB; CHAN SMT; MOORE ANJ; SCHWARTZ JC
      RATIONAL DESIGN OF BUTABINDIDE, THE FIRST INHIBITOR OF THE CHOLECYSTOKININ (CCK-8) INACTIVATING PEPTIDASE

      British Journal of Pharmacology
    88. DANVY D; MONTEIL T; PLAQUEVENT JC; DUHAMEL L; DUHAMEL P; GROS C; NOEL N; SCHWARTZ JC; LECOMTE JM
      STUDIES ON THE STRUCTURAL FEATURE OF S'1 SUBSITE OF NEPRILYSIN (EC.3.4.24.11) - STEREOCHEMICAL REQUIREMENT FOR THE ENZYME-INHIBITOR DOCKINGPROCESS

      Bioorganic & medicinal chemistry letters
    89. HULS A; PURAND K; STARK H; LIGNEAU X; ARRANG JM; SCHWARTZ JC; SCHUNACK W
      DIPHENYLMETHYL ETHERS - SYNTHESIS AND HISTAMINE H-3 RECEPTOR ANTAGONIST IN-VITRO AND IN-VIVO ACTIVITY

      Bioorganic & medicinal chemistry letters
    90. BEAUGERIE L; BAUMER P; CHAUSSADE S; BERARD H; ROZENBAUM W; PIALOUX G; LEQUINTREC Y; SCHWARTZ JC; LECOMTE JM
      TREATMENT OF REFRACTORY DIARRHEA IN AIDS WITH ACETORPHAN AND OCTREOTIDE - A RANDOMIZED CROSSOVER STUDY

      European journal of gastroenterology & hepatology
    91. ROSE C; SCHWARTZ JC
      IDENTIFICATION AND INHIBITION OF A CHOLEC YSTOKININ-INACTIVATING PEPTIDASE

      MS. Medecine sciences
    92. HULS A; PURAND K; STARK H; REIDEMEISTER S; LIGNEAU X; ARRANG JM; SCHWARTZ JC; SCHUNACK W
      NOVEL HISTAMINE H-3 RECEPTOR ANTAGONISTS WITH BENZYL ETHER STRUCTURE OR RELATED MOIETIES - SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS

      Archiv der pharmazie
    93. KRAUSE M; ROULEAU A; STARK H; LUGER P; GARBARG M; SCHWARTZ JC; SCHUNACK W
      NEW POTENT AZOMETHINE PRODRUGS OF THE HISTAMINE H-3 RECEPTOR AGONIST (R)-ALPHA-METHYLHISTAMINE CONTAINING A HETEROARYLPHENYL PARTIAL STRUCTURE

      Archiv der pharmazie
    94. GRIFFON N; PILON C; SAUTEL F; SCHWARTZ JC; SOKOLOFF P
      ANTIPSYCHOTICS WITH INVERSE AGONIST ACTIVITY AT THE DOPAMINE D-3 RECEPTOR

      Journal of neural transmission
    95. GRIFFON N; SAUTEL F; PILON C; LEVESQUE D; SOKOLOFF P; SCHWARTZ JC; DIAZ J; SIMON P; COSTENTIN J; MANN A; WERMUTH CG
      FUNCTIONAL MODELS FOR THE DOPAMINE D-3 RECEPTOR

      Biochemical Society transactions
    96. DIMITRIADOU V; ROULEAU A; TUONG MDT; LIGNEAU X; NEWLANDS GFJ; MILLER HRP; SCHWARTZ JC; GARBARG M
      RAT CEREBRAL MAST-CELLS UNDERGO PHENOTYPIC CHANGES DURING DEVELOPMENT

      Developmental brain research
    97. GRIFFON N; CROCQ MA; PILON C; MARTRES MP; MAYEROVA A; UYANIK G; BURGERT E; DUVAL F; MACHER JP; JAVOYAGID F; TAMMINGA CA; SCHWARTZ JC; SOKOLOFF P
      DOPAMINE D-3 RECEPTOR GENE - ORGANIZATION, TRANSCRIPT VARIANTS, AND POLYMORPHISM ASSOCIATED WITH SCHIZOPHRENIA

      American journal of medical genetics
    98. BUVRY A; GARBARG M; DIMITRIADOU V; ROULEAU A; NEWLANDS GFJ; TAVAKOLI R; POATY V; LOCKHART A; SCHWARTZ JC; FROSSARD N
      PHENOTYPIC AND QUANTITATIVE CHANGES IN MAST-CELLS AFTER SYNGENEIC UNILATERAL LUNG TRANSPLANTATION IN THE RAT

      Clinical science
    99. HERON A; TRAIFFORT E; ALLIX M; DIMITRIADOU V; SCHWARTZ JC
      PRODYNORPHIN MESSENGER-RNA EXPRESSION IN THE RAT DENTATE GYRUS AFTER CEREBRAL-ISCHEMIA

      Neuropeptides
    100. ROSE C; VARGAS F; BOURGEAT P; SCHWARTZ JC
      A RADIOIMMUNOASSAY FOR THE TRIPEPTIDE GLY-TRP-MET, A MAJOR METABOLITEOF ENDOGENOUS CHOLECYSTOKININ IN BRAIN

      Neuropeptides


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/08/20 alle ore 23:00:59